SEARCH:   Advanced

Blood, 15 July 2004, Vol. 104, No. 2, pp. 561-564. Prepublished online as a Blood First Edition Paper on March 25, 2004; DOI 10.1182/blood-2003-11-3801. This Article Full Text (PDF) All Versions of this Article: 2003-11-3801v1 104/2/561    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cain, J. A Articles by Tomasson, M. H Search for Related Content PubMed PubMed Citation Articles by Cain, J. A Articles by Tomasson, M. H Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 6, 2003 Accepted March 11, 2004 Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657 Jennifer A Cain, Jay L Grisolano, A D Laird, and Michael H Tomasson* Division of Oncology, Departments of Medicine and Genetics, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA Preclinical Research and Exploratory Development, 230 East Grand Avenue, SUGEN, Inc., South San Fransisco, CA, USA * Corresponding author; email: tomasson{at}im.wustl.edu. The TEL-PDGFRB fusion oncogene is associated with chronic myelomonocytic leukemia (CMML) and results in the expression of a constitutively active tyrosine kinase. SU11657 is a multi-targeted selective inhibitor of Class III/V receptor tyrosine kinases, including the PDGF, VEGF, KIT and FLT3 receptors. SU11657 inhibited TEL/PDGFR kinase activity at nanomolar concentrations and inhibited TEL-PDGFRB-mediated factor independent growth in myeloblastic 32D cells. Daily oral administration of SU11657 at 40 mg/kg suppressed myeloproliferation and significantly prolonged survival in TEL-PDGFRB mice treated prior to disease development, as well as in those with large tumor burdens. Our findings suggest that SU11657 or similar agents may have therapeutic potential in humans with hematologic malignancies expressing PDGFR fusion oncogenes. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. H. Stover, J. Chen, B. H. Lee, J. Cools, E. McDowell, J. Adelsperger, D. Cullen, A. Coburn, S. A. Moore, R. Okabe, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR{beta} and FIP1L1-PDGFR{alpha} in vitro and in vivo Blood, November 1, 2005; 106(9): 3206 - 3213. [Abstract] [Full Text] [PDF] R. Tussiwand, N. Onai, L. Mazzucchelli, and M. G. Manz Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity J. Immunol., September 15, 2005; 175(6): 3674 - 3680. [Abstract] [Full Text] [PDF] P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H.-J. Grone, J. Debus, K. E. Lipson, and A. Abdollahi Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy Cancer Res., May 1, 2005; 65(9): 3643 - 3655. [Abstract] [Full Text] [PDF] D. P. Steensma and A. F. List Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity Mayo Clin. Proc., May 1, 2005; 80(5): 681 - 698. [Abstract] [PDF] A. Abdollahi, M. Li, G. Ping, C. Plathow, S. Domhan, F. Kiessling, L. B. Lee, G. McMahon, H.-J. Grone, K. E. Lipson, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J. Exp. Med., March 21, 2005; 201(6): 925 - 935. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020